Regarding the indication of RASi treatment, the group with an indication for treatment had more severe albuminuria (A3/ProtU ≥ 50 mg/mmol) and concomitant diabetes (A2); this therefore explains their higher rates of rehospitalisation (Figure 6a) and lower survival rates (Figure 6b). The gene discussed is MMP19; the disease is diabetes mellitus.